Study on the therapeutic effect of crizotinib on MET gene mutations

Exploration on the therapeutic effect of crizotinib onMET gene mutations

Crizotinib (Crizotinib), as a multi-target tyrosine kinase inhibitor (TKI), has shown certain efficacy in the treatment of MET advanced non-small cell lung cancer (NSCLC).

The MET gene, also known as c-MET, is a proto-oncogene, and its mutation plays an important role in the occurrence and development of various malignant tumors. In NSCLC, MET gene abnormalities include MET gene amplification, MET Exon 14 skipping mutations (METex14), etc. These abnormalities are closely related to tumor proliferation, invasion and metastasis.

Crizotinib is an oral selective adenosine triphosphate complex that mainly acts on tyrosine kinase regions such as ALK, ROS1 and MET. By inhibiting the activity of these kinases, crizotinib can block the growth and spread signaling pathways of tumor cells, thereby achieving the purpose of treating tumors.

Multiple clinical studies have shown that crizotinib has a certain effect on MET patients with NSCLC patients. For example, inPROFILE In Study 1001, crizotinib showed efficacy in patients with MET advanced NSCLC Significant anti-tumor activity was demonstrated, especially in highly amplified patients, with an objective response rate (ORR) reaching 38.1%. In addition, crizotinib is also the first targeted drug proven to treat METex14, providing a new treatment option for these patients.

Although crizotinib has shown certain efficacy in patients with NSCLC mutations in the MET gene, its efficacy and drug resistance issues still need to be further explored. Some studies have shown that the efficacy of crizotinib may increase with the increase in MET amplification, but there are also problems such as off-target effects and adverse reactions. In addition, long-term use of crizotinib may lead to the emergence of drug resistance, which may be related to other mutations or bypass activation of the MET gene.